TrialSignal
Clinical trial intelligence report
A Phase 3 Randomized, Open-label (Sponsor-blind), Active-controlled, Parallel-group, Multi-center, Event Driven Study in Dialysis Subjects With Anemia Associated With Chronic Kidney Disease to Evaluate the Safety and Efficacy of Daprodustat Compared to Recombinant Human Erythropoietin, Following a Switch From Erythropoietin-stimulating Agents
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT02879305
Status
COMPLETED
Phase
Phase 3
Sponsor
GlaxoSmithKline
Executive brief
Investment-Ready Snapshot
The ASCEND-D trial evaluated the safety and efficacy of daprodustat, a novel prolyl hydroxylase inhibitor, in treating anemia associated with chronic kidney disease (CKD) in dialysis patients. Conducted by GlaxoSmithKline, the study involved 2,964 participants across 431 centers in 35 countries, comparing daprodustat to recombinant human erythropoietin (rhEPO).
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT02879305
Indication
Anaemia
Modality
small molecule
Target
Anemia in Chronic Kidney Disease
Intervention
Daprodustat, rhEPO, Placebo, Iron therapy
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.